In an inducible α-synuclein-3K::YFP neuroblastoma model, MK-8245 produced a modest improvement in induced-cell growth while also reducing growth of uninduced cells. These responses limit interpretation of the normalized growth ratio as selective rescue. [1]
In mouse embryonic fibroblasts challenged with RSL3, MK-8245 pretreatment lowered viability in resistant-serum or APOH-supplemented cultures relative to matched cultures without MK-8245. This supports its use as a cellular SCD1-directed research probe, while the combination design and absence of an MK-8245-only control limit attribution of the response to target-specific ferroptosis sensitization. [2]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Growth responses in an inducible α-synuclein neuroblastoma model
Cell-based study · Human M17D-derived 3KY19 neuroblastoma cells expressing doxycycline-inducible α-synuclein-3K::YFP, with matched uninduced cells [1]
MK-8245 showed a modest increase in growth of induced cells relative to induced DMSO controls, accompanied by reduced growth of uninduced cells. The induced/uninduced growth ratio therefore does not by itself establish selective rescue. Full growth restoration reported elsewhere in this paper concerns MF-438, not MK-8245. Figure 4 reports n = 4 (two independent wells on each of two different days), with SD error bars; no exact MK-8245 effect sizes or significance are inferred from the plotted bars.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1, 3 and 10 μM (0.1×, 0.3× and 1× of 10 μM)
- Exposure duration
- 24 h pretreatment before induction, followed by 96 h imaging after induction
- Method
- Drug treatment of cultured cells; matched doxycycline-induced and uninduced conditions
- Vehicle
- 0.1% DMSO
- Co-treatment
- Doxycycline induction of α-synuclein-3K::YFP; other test drugs were parallel comparators, not MK-8245 combinations
- Reported limits
- No numerical MK-8245 growth effect or MK-8245-specific statistical comparison is given in the Figure 4 text/caption. No biochemical SCD1 target-engagement assay is part of this selected experiment.
Methods and source locations
Compound reported in the paper: MK-8245; Compound label in the paper: MK8245 in Figure 4
Results apply to the named research compound in this engineered human neuroblastoma model; no brain exposure or clinical neuroprotection is established.
Figure 4A–D and caption; Results 2.4; Methods 4.2, 4.5–4.6; Figure 3D control
Incucyte confluence-derived growth in induced and uninduced cultures: Bright-field confluence imaging; Figure 4B normalizes the induced/uninduced growth ratio to DMSO, while panels C and D retain separate induced and uninduced responses. — Figure 4A–D and caption; Results 2.4; Methods 4.2, 4.5–4.6; Figure 3D control
MK-8245 under RSL3 challenge in serum-dependent ferroptosis resistance
Cell-based study · Mouse embryonic fibroblasts (MEFs), originally in sensitive-serum medium (Scm), with resistant-serum admixture or APOH supplementation [2]
Under RSL3 challenge, MK-8245 reduced CCK-8 viability in cultures receiving resistant-serum admixture or APOH compared with the corresponding no-MK-8245 cultures. The sensitive-serum baseline remained low with or without MK-8245. This is a combination-context cellular observation. Figure 4F does not include an MK-8245-only, no-RSL3 arm or direct SCD1 target-engagement measurement, so it cannot establish target-specific ferroptosis sensitization by itself.
Literature-Reported Treatment Conditions
- Treatment concentration
- MK-8245 80 μM; RSL3 0.3 μM; APOH 120 μg/mL where indicated
- Exposure duration
- MK-8245 for 24 h before RSL3; panel 4F does not separately specify the post-RSL3 duration
- Method
- MEFs switched from Scm to medium containing 5% S-FBS plus 5% R-FBS, or 5% S-FBS plus APOH; 10% S-FBS medium is the sensitive reference condition
- Co-treatment
- RSL3 challenge in all Figure 4F groups, with or without MK-8245; matched serum/APOH conditions
- Reported limits
- MK-8245 solvent and panel-specific exact replicate count are not specified in the read main-text methods/caption. No no-RSL3 MK-8245 control appears in Figure 4F. No exact viability percentages extracted.
Methods and source locations
Compound reported in the paper: MK-8245; Compound label in the paper: MK-8245 in Figure 4F
A high-concentration compound comparison in cultured MEFs under RSL3 challenge; not a biochemical potency estimate, single-agent cytotoxicity determination, or animal experiment.
Figure 4F and caption; Results “APOH increases the MUFA-PLs to inhibit ferroptosis”; Cell culture, Chemicals, Cell viability assay, Statistics analysis and reproducibility
CCK-8 viability after MK-8245 pretreatment and RSL3 challenge in serum/APOH conditions: CCK-8 absorbance at 450 nm; qualitative direction checked against Figure 4F. No bar-height percentages inferred. Shared statistics methods state mean ± SD and at least three independent replicates for cell-culture experiments; Figure 4 caption does not assign an exact n specifically to panel F. — Figure 4F and caption; Results “APOH increases the MUFA-PLs to inhibit ferroptosis”; Cell culture, Chemicals, Cell viability assay, Statistics analysis and reproducibility
